Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Clinical trial NCT06974786 · RECRUITING

Trial details

NCT number: NCT06974786
Sponsor: SCRI Development Innovations, LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma, Newly Diagnosed Multiple Myeloma (MM)

Start date: 2025-08-08
Primary completion: 2032-11-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.